Data Presented at NASPE Conference Support Use of Cardima Products for Heart Arrhythmias; Cardima Product Diagnoses and Treats One of the Most Common Forms of Cardiac Arrhythmias.

TORONTO--(BW HealthWire)--May 14, 1999--

Cardima(R), Inc. (Nasdaq:CRDM) today announced new data on a Cardima product used to diagnose and treat one of the most common forms of cardiac arrhythmias known as atrial fibrillation (AF). The Company believes research findings, based on its European clinical trial, support the safety of using Cardima's Revelation(TM) microcatheter to map (diagnose) and ablate (treat) tissue causing atrial fibrillation. These results were presented at Cardima's "Advances in AF Ablation" Symposium this morning at the 20th Annual North American Society of Pacing and Electrophysiology (NASPE) Conference in Toronto, Canada, taking place May 12-15, 1999.

"We believe our Revelation microcatheter is a revolutionary approach to treating patients with atrial fibrillation. Most other alternatives are expensive, painful to the patient and are not curative. Cardima is the first company to gain approval to market microcatheters that both diagnose and treat atrial fibrillation in Europe," said Phillip C. Radlick, Ph.D., President and CEO of Cardima, Inc. "Over 100 patients have already been successfully treated with the Revelation with success measured by a significant reduction in AF episodes and in some cases the absence of AF. We continue to work toward market leadership as an innovator in treating atrial fibrillation and other cardiac arrhythmias."

"The Revelation Microcatheter is a valuable tool for electrophysiologists to both map (diagnose) and ablate (treat) AF," said Zoltan Csanadi, M.D., of the Albert Szent-Gyorgyi Medical University, Hungary, one of the principal investigators in Cardima's European clinical trial. "The ease of use and the multifunctional capabilities of these microcatheters should lead to safer and more cost effective treatment options for AF patients."

Dr. Csanadi, presented results at NASPE of a multi-center study of 43 patients treated with linear radiofrequency in the right atrium for paroxysmal atrial fibrillation utilizing Cardima's Revelation microcatheter.

"Cardima's microcatheters are a unique addition to the electrophysiologist's toolbox in finding and treating arrhythmias. Catheters must be able to access areas within the heart to effectively diagnose arrhythmias so that the physician can then determine the best course of treatment for the patient," said Douglas Packer, M.D., one of the investigators in Cardima's U.S. clinical trial.

Cardima, Inc. designs, develops, manufactures and markets minimally invasive, single-use microcatheter-based systems for the dual purpose of finding and treating the two most common forms of cardiac arrhythmias: atrial fibrillation (AF), a condition of the heart characterized by the irregular and very rapid beating of the heart's atrial chambers, and ventricular tachycardia (VT), a life-threatening condition in which heartbeats are improperly initiated from within the ventricular walls, bypassing the heart's normal conduction system. Cardima is the only company developing unique microcatheter systems to be used in both diagnosing and treating AF and VT. Further information about atrial fibrillation and ventricular tachycardia can be found on Cardima's website at www.cardima.com.

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include the Company's ability to conduct successful clinical trials, obtain regulatory approvals and gain acceptance from the marketplace for its products. Additional risks are set forth in the Company's Annual Report on Form 10-K for December 31, 1998 filed with the Securities and Exchange Commission on March 19, 1999 and as amended on March 23, 1999.